Dr. Chad Beyer to provide nonclinical and clinical findings of the company’s first-in-class, System xc– activator
Milwaukee, WI – December 5, 2018 — Promentis Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing innovative therapies for neuropsychiatric disorders, announced that Senior Vice President of R&D, Dr. Chad Beyer, will present nonclinical data and initial clinical findings of SXC-2023, the company’s first-in-class activator of System xc-, at the 57th annual American College of Neuropsychopharmacology meeting in Hollywood, Florida. This poster presentation, entitled “SXC-2023: Characterization of a Novel Activator of the Cystine-Glutamate Antiporter and Potential Therapeutic for CNS Disorders” is scheduled for Wednesday December 12th.
About Promentis Pharmaceuticals
Promentis Pharmaceuticals, Inc. is a privately-held biopharmaceutical company developing innovative therapies for neuropsychiatric disorders. Promentis’ drug development efforts are focused on a unique approach to addressing glutamatergic imbalance and oxidative stress. The Company’s first indication is trichotillomania, a highly prevalent disorder for which there is no approved therapy, and for which there are no other known treatments in development.
Promentis is led by Klaus Veitinger, M.D., Ph.D. (CEO, Chairman of the Board for Promentis and OrbiMed Venture Partner). The team also includes Tom Beck, M.D. (Chief Medical Officer and Board Member for Promentis and F-Prime Capital Executive Partner), Daniel Lawton (President and Board Member) and Chad Beyer, Ph.D. (Senior VP R&D).
About Trichotillomania and Other Obsessive-Compulsive and Addictive Disorders
Obsessive-compulsive and related disorders, as defined by DSM-5, represents a broad category of neuropsychiatric disease, including OCD, excoriation (skin-picking) disorder and trichotillomania. Trichotillomania is a disabling and underrecognized condition characterized by recurrent hair pulling despite repeated attempts to stop the behavior, leading to noticeable hair loss. Trichotillomania is associated with a range of psychosocial problems, including low self-esteem, social anxiety, avoidance of intimacy, occupational impairment and an overall decrease in quality of life. In addition, a significant number of trichotillomania patients ingest their hair after pulling, which can lead to life-threatening gastrointestinal blockages requiring surgery.
Alterations in glutamate signaling within brain regions implicated in urge control and executive function have been proposed to contribute to the underlying pathology of trichotillomania, as well as other obsessive-compulsive disorders, addictive disorders and other CNS conditions. No medications are approved by the US Food and Drug Administration for the treatment of trichotillomania, nor are there any other known treatments in development.
For more information regarding trichotillomania, see: https://promentispharma.com/technology/trichotillomania.
For further information, please contact:
Promentis Pharmaceuticals
Chad E. Beyer, PhD
(e) cbeyer@promentispharma.com
Media Contact:
Tiberend Strategic Advisors, Inc.
Janine McCargo
(t) 646-604-5150
(e) jmccargo@tiberend.com